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Background: Currently there is a significant risk of infection with hepatitis B virus (HBV) during blood transfusion in
high epidemic area. This is due to the pre-seroconversion window period, immunovariant viral strains and the
presence of occult HBV infection (OBI). The aim of this study was to develop an in-house real-time PCR-based
method, which was both ultra-sensitive and efficient offering an alternative method for nucleic acid testing (NAT).
Methods: A precore fragment with 109 bp was cloned and serial diluted to standard curve construction. The
calibration of the HBV - DNA values was performed against OptiQuant® HBV-DNA Quantification Panel, Acrometrix
Europe B.V.).
Results: From our in-house plasmid we prepared serial dilutions ranging from 2 × 103 – 2 × 109 copies/ml. The
threshold was adjusted automatically during analysis and the data collected were analyzed by linear regression
(r2 = 0.99). The limit of detection for the assay with pHBVRO standards was 2000/ml in a total reaction volume of
30 μl. We found a strong correlation between the two methods (r2 = 0.9965 and p < 0.0001). The regression line
give us the following equation: Log 10 (IU/mL) = 0.9038Log 10 (copies/mL) − 1.0643, suggesting that 1 IU/mL = 15
copies/mL.
Conclusions: Therefore, we can affirm that the qHBVRO PCR can detect HBV DNA in individuals with hepatitis B at any
stage of the disease showing high capacity for NAT screening in hepatitis b donors. This results of sensitivity could
provide an advance for automation in blood banks and increasing safety of patients who receive blood transfusions.Introduction
The hepatitis B virus (HBV) is one of the most common
human pathogens and can cause hepatitis and aggressive
and advanced liver disease, including cirrhosis and hepato-
cellular carcinoma [1]. Despite the availability of a vaccine,
the implementation of preventive measures and serological
screening in blood banks remains a major public health
problem worldwide [2]. HBV can be transmitted peri-
natally, percutaneously, sexually or by horizontal transmis-
sion, especially among children, presumably through open
cuts or sores [3].* Correspondence: alcione.m@hotmail.com
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distribution, and reproduction in any mediumEarly detection of HBV surface antigen (HBsAg) signifi-
cantly reduces the risk of infection through blood transfu-
sions [4]. However, there are two situations in the course of
infection where this early detection is currently ineffective:
First, during the acute phase of infection, there is a window
period where HBsAg may be undetectable in serum [5]. In
another situation, occult infection which is defined as the
presence of HBV DNA in the liver (with or without detect-
able serum HBV DNA) may be present during the persist-
ent of infection in subjects who test negative for hepatitis B
surface antigen (HBsAg). These subjects often have very
low viral load (< 200UI/ml) [6]. Reducing the risk of trans-
mission in these situations will require increased sensitivity
the detection of HBV surface antigen (HBsAg), screening
for antibodies to HBV core antigen (anti-HBc), and contin-
ued testing and implementation of NATs [7,8].BioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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enabled the development of improved diagnostic tests
offering greater speed while maintaining excellent
levels of sensitivity and specificity [9-11]. qRT-PCR-
based detection methods have been developed for the
diagnosis of HBV and other pathologies in clinical la-
boratories [12-14].
To successfully monitor viral load, it is important to
diagnose viral replication, establish the prognosis of liver
disease, to assess the risk of disease progression, to iden-
tify patients who need antiviral therapy and to monitor
the virologic response to treatment. Currently there are
several types of detection and quantitation assays in use,
with varying levels of success [15,16]. The aim of this
study was to develop an in-house real-time PCR-based
method, which was both ultra-sensitive and effective, of-
fering a new NAT alternative.
Materials and methods
Clinical samples
This study included 134 patients with chronic HBV in-
fection who were treated at the Viral Hepatitis Clinic
Specialized Center of Research in Tropical Medicine in
Rondonia (CEPEM). A control group of 30 donors, who
all tested negative por ELISA for human immunodefi-
ciency virus (HIV) 1 and 2, HBsAg, anti-HBc and anti-
HCV, and who attended the blood bank of the State of
Rondonia (FHEMERON) was included in the study. We
also included 10 and 26 serum samples from individuals
with chronic HCV and co-infection with HBV/HDV
respectively.
Ethical consent
This study was approved by the Brazilian Institutional
Ethics Committee of the Centro de Pesquisa em Medicina
Tropical (CEPEM), with process number 107/10. Written,
informed consent was obtained from each patient for the
publication of this manuscript and any accompanying
images.
DNA extraction
Viral DNA extraction was performed using the QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany) and 200 μl of
serum according to the manufacturer’s instructions.
Three samples with viral load known were tested: first
with high viral load and the others medium and low viral
load. After this were diluted with final volume 200 ul, 100 ul
and 50 ul. Besides, HBV DNA was extracted from 22
samples of individuals with same profile serological: total
isolated anti-HBc. These samples were diluted in 50 uL
and 200 uL to optimize the final volume of extraction for
samples with low viral load. Subsequently the samples
were submitted to reaction for sensitivity analysis. Precipi-
tated DNA was resuspended in elution buffer and storedat −20°C until further use. To avoid false-positive results,
we followed strict procedures for nucleic acid amplifica-
tion [17].
In-house testing
Primer concentrations were optimized using a concen-
tration gradient ranging from 100–900 nM and SYBR®
Universal PCR Master Mix (Applied Biosystems, Foster
City, CA, USA). TaqMan® probe concentrations were simi-
larly optimized using a concentration gradient ranging
from 50–300 nM.
Ultra-sensitive real-time PCR
The assay was performed on an ABI 7500 platform (Applied
Biosystems) with 30 μl reaction volumes containing 15 μl
TaqMan® Universal Master Mix (Applied Biosystems), 3 μl
HBVRO1 forward primer (5′-AGGAGGCTGTAGGCAT-
AAATTGG 3′), 3 μl reverse primer (5′-GCACAGCTTGG
AGGCTTG-3′), 0.6 μl probe (5′-FAM TCACCTCTGCC
TAATC-3′-MGB, 6 μl extracted DNA and 2.4 μl of water.
Construction of the standard curve
To construct the standard curve, we initially used conven-
tional PCR with amplification of a 109 bp fragment in the
pre-core region according Kavita 2006 adapted, selecting
five samples with known viral load. Approximately 50 ng
of DNA was used per reaction with a final volume of
50 μl. Amplification was performed on an ABI Prism 7500
Veriti (Applied Biosystems) with an initial denaturation
temperature of 94°C for 5 min, followed by 40 cycles of
94°C for 1 min, 58°C for 45 sec, 72°C for 1 min and a final
extension of 10 min at 72°C. The selected fragment was
purified, ligated to the p-GEM-T Easy® vector (Promega,
New York, USA), cloned into a prokaryotic system and
subsequent linearization with PstI (Invitrogen™ Life Tech-
nologies, Carlsbad, CA, USA). Absolute quantitation was
used to determine the exact number of DNA molecules
for estimating viral load.
Inter- and intra-assay variation and reproducibility of real-
time PCR
To determine intra-experimental variation, we tested the
reproducibility of six HBV-positive sera with different
viral loads, in duplicate, in the same reaction setup. The
same set of samples was used in three experiments per-
formed on different days, to estimate inter-experimental
variation in the estimation of viral load. Reproducibility
was estimated by calculating the coefficient of variation
(CV), which is calculated as the ratio of the standard de-
viation and the mean of the replicates.
HBV DNA quantification
Calibration curves for HBV DNA were constructed
using the OptiQuant® HBV-DNA Quantification Panel,
Figure 1 qHBVRO standard curve as determined by
linear regression.
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prepared from the standards included in the kit, ranging
from 2 × 102 – 2 × 106 IU/ml. For our in-house plasmid,
pHBVRO, a serial dilution was prepared with a range 2 ×
103 – 2 × 109 copies/ml. The concentration was measured
spectrophotometrically both by using a NanoDrop® ND-
1000 (Thermo Scientific NanoDrop Products, Wilming-
ton, Delaware), and the measurements were recorded in
units of nanograms per microliter, which was converted
into copies per microliter by using the following equation:
([x ng/μL × 10-9] / [p-GEM-T Easy® vector and 109 HBV
DNAbps × 660]) × 6.022e23 = y copies/μL. Using linear
regression a standard curve was constructed, which
was used to convert copies/ml to standard international
units (IU/ml).Quantification panel
To compare the performance of our in-house method
(qHBVRO) with that of the commercial kit, OptiQuant®
HBV-DNA Quantification Panel (AcroMetrix® Europe
BV), we tested 100 serum samples collected from pa-
tients chronically infected with HBV.Table 1 Intra-experimental variation in the qHBVRO assay for
qHBV RO - in
Sample 1st run (IU/mL) 2nd run (IU/mL) 3th run
1 4.6 × 106 4.6 × 106 4.6
2 2.8 × 104 2,7 × 104 2.7
3 5.0 × 102 4.3 × 102 4.6
4 3.2 × 102 2.9 × 102 2.7
5 3.3 × 105 3.1 × 105 3.0
6 4.8 × 104 4.0 × 104 4.3Statistical analysis
The correlation between the AcroMetrix® test kit and the
qHBVRO assay was calculated using GraphPad 5.0 (Graph-
Pad software) and a two-tailed Pearson′s correlation test
with a confidence interval of 95%. The units for measuring
viral load (copies/ml and IU/ml) were transformed to log
base 10.
Analytical specificity
We tested 30 samples from blood donors, 10 serum sam-
ples from mono-infected HCV patients, 28 samples from
patients co-infected with HBV/HDV and 15 samples that
were judged indeterminate for HBV surface antigen by the
Serology Laboratory of Viral Hepatitis Clinic - IPEPATRO.
All samples were submitted to qHBV PCR to determine
viral load.
Analytical sensitivity
We selected 15 sera, which were considered indetermin-
ate for HBsAg by ELISA when tested in duplicate and
which had absorbance values within the gray zone, or ±
10% cut-off confidence interval. These samples were
subjected to three separate assays, with each sample per-
formed in duplicate to evaluate the performance of our
assay in detecting uncertain samples.
Results
Analytical sensitivity and efficiency
From our in-house plasmid we prepared serial dilutions
ranging from 2 × 103 – 2 × 109 copies/ml. The concen-
tration of primers used was 300 nM, for both primers,
and 100 nM for the probe. The threshold was adjusted
automatically during analysis and the data collected were
analyzed by linear regression (r2 = 0.99), Figure 1. The
limit of detection for the assay with pHBVRO standards
was 2000/ml in a total reaction volume of 30 μl. Two
positive samples with known viral load were used as in-
ternal controls. HBV DNA extraction was patterned on
elution of 200 μl because there was no significant vari-
ation in sensitivity of method in different volumes of
patients with intermediate and high viral load. But the
22 samples of patients with serological profile “anti-HBcserum samples
tra assay
(IU/mL) Avarage inter assay SD CV
× 106 4.6 × 106 0.027 × 106 0,01
× 104 2.7 × 104 0.025 × 104 0,01
× 102 4.6 × 102 0.36 × 102 0,08
× 102 3.0 × 102 0.26 × 102 0,09
× 105 3.2 × 105 0.16 × 105 0,05
× 104 4.4 × 104 0.38 × 104 0,09
Table 2 Inter-experimental variation in the qHBVRO assay for serum samples
qHBV RO - inter assay
Sample 1st run (IU/mL) 2nd run (IU/mL) 3th run (IU/mL) Avarage inter assay SD CV
1 4.6 × 106 5.0 × 106 4.6 × 106 4.7 × 106 0.02 × 106 0,05
2 2.7 × 104 3.4 × 104 27 × 104 2.9 × 104 0.004 × 104 0,14
3 4.3 × 102 4.6 × 102 4.0 × 102 4.3 × 102 0.3 × 102 0,07
4 3.2 × 102 2.7 × 102 3.0 × 102 3.0 × 102 0.2 × 102 0,08
5 3.3 × 105 3.0 × 105 2.8 × 105 3.0 × 105 0.2 × 105 0,08
6 5.0 × 104 4.9 × 104 4.0 × 104 4.6 × 104 0.5 × 104 0,11
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negative on both elution, 5 samples were positive only in
elution of 50 uL within which 2 samples were positive in
both elution.
Inter- and intra-assay variation and reproducibility of real-
time PCR
The six HVB-DNA positive sera tested showed no statis-
tical differences between repeats. The coefficient of vari-
ation was similar in both high and low viral load samples
(0.01-0.16%), indicating the same efficiency of amplification
for varying viral loads. There was no statistical difference in
intra-and inter-assay variation (CV), which confirmed the
reproducibility of the assay (Tables 1 and 2).
Validation of the qHBVRO method
Using linear regression, we found a strong correlation
between the qHBVRO assay and the AcroMetrix® HBV-
DNA kit (r2 = 0.998 and p <0.0001) as shown in Figure 2.
Viral load values between the AcroMetrix® HBV-DNA
and the qHBVRO assay were compared for 134 patients
by Pearson’s correlation. We found a strong correlation
between the two methods (r2 = 0.9965 and p < 0.0001).
The regression line give us the following equation:Figure 2 WHO 1st International Standard (HBV ® kit Acrometrix
DNA) as determined by linear regression.Log 10 (IU/mL) = 0.9038Log 10 (copies/mL) − 1.0643,
suggesting that 1 IU/mL = 15 copies/mL (Figure 3).Analytical specificity and detection performance of
indeterminate for ELISA samples and anti-HBc isolated
samples
Of the 15 indeterminate for ELISA samples tested, six
were positive for HBV DNA by both methods (Table 3).
All samples that were classified as negative by ELISA were
confirmed as such as shown. Of the 22 samples isolated
anti-HBc eluted in 50 uL, 5 were positive (Figure 4).Discussion
Currently, there is a significant risk of infection with hepa-
titis B virus (HBV) during blood transfusions. This is due
to the pre-seroconversion window period, immunovariant
viral strains and the presence of occult HBV infection
(OBI) [8,18,19]. Combined detection of HBsAg and anti-
HBc constitutes an important strategy in donor screening
which excludes the vast majority of OBIs [20-22]. How-
ever, in many countries, especially in areas of low HBV
prevalence (< 3%) these strategies are inefficient especially
during the pre-seroconversion window period. However,
in countries with high prevalence of positivity forFigure 3 Analytical sensitivity of qPCR HBV demonstrated with
97 samples: 91 samples positive for HBsAg and 6 samples total
anti-HBc isolated. These 6 samples were DNA-HBV positive detected
within 50 clinical samples tested in patients with profile total anti-HBc
isolated. The dashed line is the limit of analytical detection of
qPCR HBV.
Table 3 Data summary for indeterminate samples
1st run (Ct*) 2nd run (Ct*) 3th run (Ct*) Mean SD CV Log10 IU/ml DO* Cut-off
1 37.31 37.56 37.74 37.54 0.21595 1% 0.69 0.086 0.062
2 38.90 38.98 39.1 38.99 0.10066 0% 0.31 0.075 0.079
3 38.69 38.83 38.95 38.82 0.13013 0% 0.35 0.070 0.063
4 37.47 37.54 37.87 37.63 0.21362 1% 0.66 0.062 0.065
5 39.05 39.1 39.45 39.20 0.21794 1% 0.25 0.060 0.068
6 38.94 39.03 39.26 39.08 0.16503 0% 0.28 0.069 0.068
DO*: Optical Density by spectrophotometry (ELISA).
Ct*: Amplification cycle in the assay qHBVRO.
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exclusion of several potential donors leading to a de-
crease of blood products in various regions - such as the
failure to block potential donors with OBI - keeping
present the risk of post-transfusion HBV [18,23]. The
qHBVRO test presents an excellent alternative to HBV
detection and quantification because it allows significant
reduction in the risk of transmission during the window
period as well as improved detection of occult HBV.
In this study we developed a qRT-PCR assay for the
identification and quantification of HBV DNA with an ef-
ficiency of 94.06% and good correlation with the currently
used commercial test: WHO 1st International Standard
(HBV ® kit Acrometrix DNA), r = 0.998, p < 0.0001. The
qHBVRO PCR test was 100 fold more sensitive, allowing
detection of up to two thousand copies per ml of serum in
HBV-infected individuals. Our method also proved to be
more sensitive than other in-house qRT-PCRs [24-26],
and could detect occult hepatitis B infections as well as
cases which were inconclusive by ELISA, using only 6 μl
of DNA extracted from 200 μl of serum in final reaction
volume of 30 μl for qHBVRO. However, was observed that
in cases of samples with low viral load is important to
consider a smaller volume in the elution of DNA. It is the
case of 22 samples tested from individuals with isolated
anti-HBc where 5 were positive in 50 uL elution and only
2 were positive on PCR qHBV. These results reinforce the
importance that in case of occult infection or immunologicalFigure 4 Analytical specificity of samples that tested positive,
undetermined, negative and anti-HBc alone by ELISA using the
qPCR HBV in house.window period, the concentration of DNA is an important
factor to consider.
The high analytical specificity of the test, using sam-
ples from individuals that tested positive, negative and
indeterminate for HBsAg by ELISA demonstrates that
qHBVRO PCR can detect HBV DNA in individuals with
hepatitis B at any stage of the disease, qualifying it as an
important alternative NAT. The qHBVRO assay is highly
reproducible, with low intra- and inter-experimental
variation of between 0-1% (CV), whereas other in-house
tests, which are considered to have good reproducibility,
show experimental variation of 4.94–10.59% [27-31].
Our method proved to be efficient, sensitive, specific
and reproducible in the detection of occult HBV, and
could therefore be used for nucleic acid testing (NAT) in
blood banks to prevent HBV transmission by blood trans-
fusion. The advantages of NAT relating to cost and effect-
iveness compared with serological diagnostics have been
widely debated [28-30]. It has been suggested that NAT
offers advantages in many instances including occult infec-
tions, in the confirmation of viremia, for screening blood-
and organ-donors, discriminating between patients with
chronic or acute infection which has been resolved,
diagnosis of perinatal infection, solving indeterminate
serological results, monitoring patients on antiviral
therapy and to identify the virus in immunocomprom-
ised individuals [31-33].Conclusion
In conclusion, the real-time PCR assay qHBVRO is ap-
propriate for the quantification of HBV DNA in serum
samples. This test is reproducible and proved be sensi-
tive detecting samples with low viral load. Therefore, we
can affirm that the qHBVRO PCR can detect HBV DNA
in individuals with hepatitis B at any phase of disease
showing good NAT screening for hepatitis B. Samples of
patients anti-HBc positive isolated were selected and
submitted to qHBVRO test to enhancing sensitivity the
this results. This developed test may be automated and
used in blood banks, increasing safety of patients who
receive blood transfusions.
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